I
Immunai
Mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes
News
Open roles
Immunai in the New York City ecosystem
The Immunai office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Series A4 investors entered at this stage
- DPDexcel Pharma
- SFSchusterman Foundation
- CMCatalio Capital Management
- DODuquesne Family Office
Source: Dealroom Talent Intelligence.
Alumni founders
Former Immunai employees who went on to found companies, sorted by Dealroom signal score.
PHPhaseVEst. 2023
Raviv PrylukIsrael
JHJimini HealthEst. 2023
Luis VolochUnited States
Fabian TheisGermany
SBSanta Ana BioEst. 2021
Danny WellsUnited StatesPatents
3 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Immunai on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.




